Introduction
Leading pharmaceutical company secured regulatory approvals in Azerbaijan and Philippines, received product registrations, and expects GMP clearance to expand exports across multiple international markets.
Also Read: GRM Overseas Limited launches 10X basmati rice for diabetics, stock in focus
Share price movement of Beta Drugs
On April 22, 2026, Beta Drugs Limited opened at ₹1,326.20, up 0.74% from its previous close of ₹1,316.50. The stock reached a high of ₹1,405.50 (6.78%) and a low of ₹1,322.10. By 11:48 AM, it traded at ₹1,333.90, a 1.32% increase, with a market cap of ₹1,352.16 crore.
Beta Drugs Expands Global Reach
Beta Drugs Limited reported regulatory progress in Azerbaijan and Philippines. The company completed inspection of its manufacturing facility by Azerbaijan Ministry of Health from 13 April to 17 April 2026.
The company expects GMP approval in one to two months. In the Philippines, it received Certificates of Product Registration for two brands, both first generic approvals in the market.
Further approvals are expected over six months for expansion in Southeast Asia. The company holds multiple international certifications and has triggered EU GMP inspection to strengthen export market presence.
Stock performance of Beta Drugs for period of 1 week, 6 months, and 1 year
Beta Drugs Limited delivered a 1-week return of -5.32%, a 6-month return of -26.9%, and a 1-year return of -28.2%.
Also Read: Indo SMC Limited bags ₹28 crore order from mining and steel major, stock up 5%
Shareholding pattern of Beta Drugs
| Particulars | Mar 2026 | Dec 2025 | Sep 2025 |
| Promoter | 64.60% | 64.90% | 66.70% |
| FII | 1.20% | 1.10% | 0.90% |
| DII | 2.20% | 1.90% | 0.30% |
| Public | 32.10% | 32.10% | 32.10% |
About Beta Drugs
Beta Drugs Limited (NSE: BETA) manufactures oncology drugs and operates in domestic and export markets with a focus on anti-cancer pharmaceutical products in India.
Stay Ahead with the Latest Stock Market Updates – Click Here
Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time. The securities quoted are exemplary and are not recommendatory.
FAQs
Q: Why is Beta Drugs Limited share price rising today?
A: Beta Drugs Limited share price is rising after receiving regulatory approvals in Azerbaijan and Philippines, expanding export market access.
Q: What is Beta Drugs Limited’s main business focus?
A: Beta Drugs Limited manufactures oncology and anti-cancer drugs with operations in domestic and export pharmaceutical markets.
Q: What are the 52-week high and low of Beta Drugs Limited stock?
A: Beta Drugs Limited stock recorded a 52-week high of Rs 2,000.00 and a 52-week low of Rs 990.10.
